Nancy Potvin
Acute Care · Pittsfield, MANPI 1144878216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Sanofi at 25.6% of the total. Reporting peaked in 2021 at $753 and has fallen 53.9% since, to $347 in 2025.
Across 49 payments — averaging $44.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$555
- AstraZeneca$458
- Regeneron Healthcare Solutions, Inc.$398
- GSK$327
- Sanofi-aventis U.S. LLC$180
- Verona Pharma, Inc.$124
- plus $126 from 2 others
What the payments were for
- Food & beverage$1,98892%
- Education$1808%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $555 |
| AstraZeneca | 5 | $458 |
| Regeneron Healthcare Solutions, Inc. | 10 | $398 |
| GSK | 18 | $327 |
| Sanofi-aventis U.S. LLC | 2 | $180 |
| Verona Pharma, Inc. | 1 | $124 |
| Boehringer Ingelheim | 1 | $65 |
| Amgen | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$260
- TEZSPIRE$126
- Ohtuvayre$124
- TRELEGY ELLIPTA$116
How this compares
$2,168 in reported general payments places this provider in the 85th percentile of 307 acute care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 783 | $696,480 |
| Dupixent PenDupilumab | 100 | $358,915 |
| Breo ElliptaFluticasone/Vilanterol | 474 | $248,205 |
| OfevNintedanib Esylate | 13 | $169,134 |
| NucalaMepolizumab | 47 | $166,071 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 191 | $113,595 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 119 | $79,836 |
| Incruse ElliptaUmeclidinium Bromide | 152 | $73,702 |
| Spiriva RespimatTiotropium Bromide | 93 | $67,894 |
| Advair HfaFluticasone Propion/Salmeterol | 100 | $52,658 |
| SymbicortBudesonide/Formoterol Fumarate | 163 | $52,244 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 75 | $50,174 |
| Spiriva HandihalerTiotropium Bromide | 42 | $40,896 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 54 | $29,093 |
| Ventolin HfaAlbuterol Sulfate | 355 | $28,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $327 | $1,319,7621,705 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $65 | $316,295235 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $458 | $159,115347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 307 acute care providers in Massachusetts.
Other acute care in Pittsfield
- Bridgid JosephBoston$110K
- Pamela CalareseBoston$106K
- Kimberly GuiboneBoston$86K
- Audrey RoseWoburn$58K
- Danielle BeaulieuWest Springfield$21K
- Dawn NaylorBoston$13K
- Rebecca RathburnBoston$13K
- Morgan BowdenBoston$11K
- Javier RiveraBoston$11K
- Catherine CollierFramingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.